Full Year 2024 Results Key Financial Results Revenue: US$4.44b (flat on FY ...

Elanco Animal Health Inc (ELAN) reports robust organic growth and significant debt reduction, setting a positive outlook for ...

Morgan Stanley lowered the firm’s price target on Elanco (ELAN) to $13 from $14 and keeps an Equal Weight rating on the shares. Q4 EPS of 14c ...

Barclays lowered the firm’s price target on Elanco (ELAN) to $19 from $20 and keeps an Overweight rating on the shares. The firm sees a “solid ...

Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health’s Fourth Quarter 2024 Earnings Conference ...

Animal health company Elanco (NYSE:ELAN) will be announcing earnings results tomorrow before market open. Here’s what to look ...

Elanco Animal Health inks agreement with Medgene to commercialize highly pathogenic avian influenza vaccine in dairy cattle: Greenfield, Indiana Wednesday, February 26, 2025, 15:0 ...

Elanco's Q4 revenue reached $1.02 billion, topping estimates, but EPS missed forecasts. 2025 guidance lags consensus as currency headwinds pose a $110 million challenge.

Elanco Animal Health will commercialize an avian flu vaccine for dairy cattle after reaching an agreement with Medgene.

Elanco Animal Health Incorporated (NYSE:ELAN – Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday after the company announced weaker than expected quarterly earnings.

Elanco Animal Health narrowed its fourth-quarter loss despite lower sales, but its forecast for the current quarter and full year came in below Wall Street's estimates.

A global manufacturer acquired a Shawnee facility in the fall, the third time it and its 300 employees have changed hands ...